Article ; Online: Mucormycosis in Burns: A Review.
Journal of burn care & research : official publication of the American Burn Association
2022 Volume 43, Issue 2, Page(s) 353–360
Abstract: Mucormycosis is a rare fungal infection with a high mortality rate. It presents with scattered black/necrotic ulcers, white fungal elements, and progression of wounds despite seemingly adequate debridement. Diagnosis is confirmed on wound histology; ... ...
| Abstract | Mucormycosis is a rare fungal infection with a high mortality rate. It presents with scattered black/necrotic ulcers, white fungal elements, and progression of wounds despite seemingly adequate debridement. Diagnosis is confirmed on wound histology; however, this is often delayed. There is currently no comprehensive review of burn-related mucormycosis within the literature, making this the first article to provide evidence-based treatment guidance. We performed a review of publications from 1946 to the present. There were 151 cases of mucormycosis complicating burns. The mortality rate was 54.5%, and there was a significant increase in mortality with axial body site involvement compared with isolated peripheral involvement. The standard treatment was prompt and radical debridement. Utilization of frozen section to guide debridement aided in clinical decision making. No systemic treatment reached statistical significance; however, amphotericin B trended toward significance. Although there is no strong evidence for topical amphotericin B or hyperbaric oxygen, there may be benefit in some cases. This study recommends early radical debridement in conjunction with the European Confederation of Medical Mycology guidelines of IV liposomal/lipid complex amphotericin B more than 5mg/kg/day, with posaconazole 800 mg daily in divided doses as a salvage or oral step-down. |
|---|---|
| MeSH term(s) | Amphotericin B/therapeutic use ; Antifungal Agents/therapeutic use ; Burns/drug therapy ; Burns/therapy ; Debridement/adverse effects ; Humans ; Mucormycosis/drug therapy ; Mucormycosis/therapy |
| Chemical Substances | Antifungal Agents ; Amphotericin B (7XU7A7DROE) |
| Language | English |
| Publishing date | 2022-01-07 |
| Publishing country | England |
| Document type | Journal Article ; Review |
| ZDB-ID | 2224246-6 |
| ISSN | 1559-0488 ; 1559-047X |
| ISSN (online) | 1559-0488 |
| ISSN | 1559-047X |
| DOI | 10.1093/jbcr/irab236 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 6223: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.